We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Draws Complete Response Letter Over Third-Party Manufacturer
Sanofi Draws Complete Response Letter Over Third-Party Manufacturer
The FDA issued a complete response letter (CRL) to Sanofi for sutimlimab, an investigational monoclonal antibody for treating hemolysis in adults with the rare autoimmune condition, cold agglutinin disease.